1. Home
  2. PLX

PLX

Protalix BioTherapeutics Inc. (DE)

Logo Protalix BioTherapeutics Inc. (DE)

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-17-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Founded: 1993 Country:
United States
United States
Employees: N/A City: HACKENSACK
Market Cap: 86.2M IPO Year: 1998
Target Price: $10.00 AVG Volume (30 days): 345.7K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.09 EPS Growth: N/A
52 Week Low/High: $1.17 - $3.55 Next Earning Date: 05-02-2024
Revenue: $65,494,000 Revenue Growth: 37.48%
Revenue Growth (this year): 14.21% Revenue Growth (next year): 71.95%

Share on Social Networks: